Intracytoplasmic sperm injection (ICSI) using cryopreserved sperm from men with malignant neoplasm yields high pregnancy rates

ObjectiveTo investigate the efficacy of IVF–intracytoplasmic sperm injection (ICSI) in patients who cryobanked semen before cancer treatment.DesignRetrospective consecutive study.SettingUniversity-based IVF unit.Patient(s)One hundred eighteen couples undergoing IVF-ICSI using pretreatment frozen sperm.Intervention(s)Treatment follow-up.Main Outcome Measure(s)Semen parameters and clinical pregnancy rates.Result(s)One hundred eighteen couples underwent 169 IVF cycles using pretreatment cryopreserved sperm; the average sperm count was 66.5 × 106/mL, and the average motility was 45.6%. Post-thaw sperm average density was 40.9 × 106/mL with 14.2% motility. The clinical pregnancy rate was 56.8% per retrieval; 96 pregnancies were achieved, resulting in 126 children born and 11 spontaneous abortions. Patients with prostate cancer had the worst semen parameters before sperm banking and the lowest clinical pregnancy rates.Conclusion(s)IVF-ICSI is the recommended treatment for most couples with cryopreserved sperm for male cancer. High pregnancy and delivery rates after IVF-ICSI using cryopreserved sperm from patients with cancer should encourage all reproductive-age males to cryobank semen immediately after diagnosis; physicians should discuss this and advise freezing multiple samples before treatment.